Allogene Therapeutics, Inc.

1. 01

   Behind SPY and its sector fund XLV over 1 year

   1 month: −18.5% (SPY −1.6%, XLV +13.5%). 3 months: −39.0% (SPY −0.4%, XLV +15.5%). 1 year: +7.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: ALLO, SPY and XLV · as of 4 Nov 2026

2. 02

   14.4% above its 52-week low

   Closed at $1.19 on 4 Nov 2026: 73.3% below the 52-week high of $4.46 (13 Apr 2026) and 14.4% above the low of $1.04 (7 Nov 2025).

   Daily price bars, split-adjusted · as of 4 Nov 2026

3. 03

   9.3 days to cover short interest

   53.4M shares were sold short at the 15 Oct 2026 settlement, 15.5% of the 345.5M shares outstanding; covering them would take 9.3 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   Below its 50- and 200-day averages

   The 4 Nov 2026 close of $1.19 was 23.7% below its 50-day average ($1.56) and 39.7% below its 200-day average ($1.97). It has closed below the 200-day for 42 sessions, since 8 Sep 2026. The 50-day average crossed below the 200-day on 9 Sep 2026, 40 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

5. 05

   Volume 2.3× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 16.5M shares was 2.3× the average of the 30 sessions before it (7.3M), as the price rose 6.2%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close